- CytoSorbents Reports First Quarter 2024 Results
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
- CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
More ▼
Key statistics
On Friday, Cytosorbents Corp (CTSO:NAQ) closed at 0.9001, 15.10% above the 52 week low of 0.782 set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.885 |
---|---|
High | 0.91 |
Low | 0.86 |
Bid | 0.8703 |
Offer | 1.00 |
Previous close | 0.88 |
Average volume | 71.32k |
---|---|
Shares outstanding | 54.31m |
Free float | 52.57m |
P/E (TTM) | -- |
Market cap | 48.88m USD |
EPS (TTM) | -0.5869 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼